This study focuses on Myelodysplastic Syndrome, a condition where the bone marrow does not produce enough healthy blood cells. The research specifically looks at patients with low-risk form of this disease who have anemia (low red blood cell counts) and require regular blood transfusions. The study will test a new medication called momelotinib, which is given as tablets taken by mouth.

The purpose of this research is to determine if momelotinib can help patients become less dependent on blood transfusions. The study will be conducted in two parts – first to find the right dose of the medication, and then to see how well it works in reducing the need for blood transfusions over a 24-week period.

During the study, participants will receive momelotinib tablets and will be monitored for how their body responds to the treatment. The researchers will track how many blood transfusions patients need and will also check for any side effects of the medication. The total treatment period may last up to 76 weeks, during which patients will have regular check-ups to monitor their health and blood counts.